Skip to content
naulon
Not checkedNot checked for notices yet.

Primary Renal Synovial Sarcoma- A Diagnostic Challenge

Netra P Kori, Ranjana Shashidhar Ranade, Aneel Myageri

National Journal of Laboratory Medicine · 2021

doi:10.7860/njlm/2021/47194:2480 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Synovial sarcoma arising primarily in kidney is very rare, accounting for <2% of all malignant renal neoplasms. This tumour poses diagnostic dilemma as it mimics histologically with many other commonly presenting kidney tumours. Here, a 32-year-old female is reported who presented with gross haematuria and flank pain for three months. She complained recent increase in frequency of micturition, poor stream and incomplete emptying of bladder. Clinical possibility of urinary tract infection, urolithiasis, and renal neoplasm were considered. Right lower pole renal mass lesion of soft tissue density measuring 7.2×8.1×6.4 cm was found on radiologic examination. Grossly, well-circumscribed fleshy friable tumour with microcystic and haemorrhagic areas were noted. Monotonous small blue round cells arranged in sheets and in peritheliomatous pattern was noted upon microscopic examination. Histopathological differentials included were ewing sarcoma, adult wilm tumour, Non-Hodgkin Lymphoma (NHL) and rhabdomyosarcoma. A remote possibility of synovial sarcoma was also considered. Immunohistochemistry (IHC) revealed positivity with CD99, CD56, Bcl2 and TLE1. Characteristic histomorphology aided by typical immunohistochemical findings unravelled a diagnostic surprise of a rare renal tumour Primary Renal Synovial Sarcoma (PRSS).

Abstract licence: CC BY-NC-ND

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.